These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
397 related articles for article (PubMed ID: 19329178)
21. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997 [TBL] [Abstract][Full Text] [Related]
22. Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure. Sato N; Takahashi W; Hirayama A; Ajioka M; Takahashi N; Okishige K; Wang X; Maki A; Maruyama H; Ebinger U; Yamaguchi M; Pang Y; Matsumoto H; Kawana M Circ J; 2015; 79(6):1237-47. PubMed ID: 25912697 [TBL] [Abstract][Full Text] [Related]
23. Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. Teerlink JR; Felker GM; McMurray JJV; Ponikowski P; Metra M; Filippatos GS; Ezekowitz JA; Dickstein K; Cleland JGF; Kim JB; Lei L; Knusel B; Wolff AA; Malik FI; Wasserman SM; J Am Coll Cardiol; 2016 Mar; 67(12):1444-1455. PubMed ID: 27012405 [TBL] [Abstract][Full Text] [Related]
24. Worsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF Studies. Davison BA; Metra M; Cotter G; Massie BM; Cleland JGF; Dittrich HC; Edwards C; Filippatos G; Givertz MM; Greenberg B; Ponikowski P; Voors AA; O'Connor CM; Teerlink JR; JACC Heart Fail; 2015 May; 3(5):395-403. PubMed ID: 25951761 [TBL] [Abstract][Full Text] [Related]
25. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. McMurray JJ; Teerlink JR; Cotter G; Bourge RC; Cleland JG; Jondeau G; Krum H; Metra M; O'Connor CM; Parker JD; Torre-Amione G; van Veldhuisen DJ; Lewsey J; Frey A; Rainisio M; Kobrin I; JAMA; 2007 Nov; 298(17):2009-19. PubMed ID: 17986694 [TBL] [Abstract][Full Text] [Related]
26. Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. Metra M; Ponikowski P; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Hua TA; Severin T; Unemori E; Voors AA; Teerlink JR Eur Heart J; 2013 Oct; 34(40):3128-36. PubMed ID: 23999454 [TBL] [Abstract][Full Text] [Related]
27. Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study. Felker GM; Mentz RJ; Teerlink JR; Voors AA; Pang PS; Ponikowski P; Greenberg BH; Filippatos G; Davison BA; Cotter G; Prescott MF; Hua TA; Lopez-Pintado S; Severin T; Metra M Eur J Heart Fail; 2015 Dec; 17(12):1262-70. PubMed ID: 26333655 [TBL] [Abstract][Full Text] [Related]
28. Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF. Metra M; Davison BA; Gimpelewicz C; Carubelli V; Felker GM; Filippatos G; Greenberg BH; Hua TA; Liu Z; Pang PS; Ponikowski P; Severin TM; Voors AA; Wang Y; Cotter G; Teerlink JR Int J Cardiol; 2018 Feb; 253():91-96. PubMed ID: 29306479 [TBL] [Abstract][Full Text] [Related]
29. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Konstam MA; Neaton JD; Dickstein K; Drexler H; Komajda M; Martinez FA; Riegger GA; Malbecq W; Smith RD; Guptha S; Poole-Wilson PA; Lancet; 2009 Nov; 374(9704):1840-8. PubMed ID: 19922995 [TBL] [Abstract][Full Text] [Related]
30. First clinical experience with intravenous recombinant human relaxin in compensated heart failure. Dschietzig T; Teichman S; Unemori E; Wood S; Boehmer J; Richter C; Baumann G; Stangl K Ann N Y Acad Sci; 2009 Apr; 1160():387-92. PubMed ID: 19416226 [TBL] [Abstract][Full Text] [Related]
36. Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. Erdmann E; Semigran MJ; Nieminen MS; Gheorghiade M; Agrawal R; Mitrovic V; Mebazaa A Eur Heart J; 2013 Jan; 34(1):57-67. PubMed ID: 22778174 [TBL] [Abstract][Full Text] [Related]
37. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Tissot AC; Maurer P; Nussberger J; Sabat R; Pfister T; Ignatenko S; Volk HD; Stocker H; Müller P; Jennings GT; Wagner F; Bachmann MF Lancet; 2008 Mar; 371(9615):821-7. PubMed ID: 18328929 [TBL] [Abstract][Full Text] [Related]
38. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744 [TBL] [Abstract][Full Text] [Related]
39. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Tavazzi L; Maggioni AP; Marchioli R; Barlera S; Franzosi MG; Latini R; Lucci D; Nicolosi GL; Porcu M; Tognoni G; Lancet; 2008 Oct; 372(9645):1223-30. PubMed ID: 18757090 [TBL] [Abstract][Full Text] [Related]
40. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Zannad F; Cannon CP; Cushman WC; Bakris GL; Menon V; Perez AT; Fleck PR; Mehta CR; Kupfer S; Wilson C; Lam H; White WB; Lancet; 2015 May; 385(9982):2067-76. PubMed ID: 25765696 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]